IL168300A - Modified catalase proteins useful for promotion of peroxisomal catalase function in cells - Google Patents
Modified catalase proteins useful for promotion of peroxisomal catalase function in cellsInfo
- Publication number
- IL168300A IL168300A IL168300A IL16830005A IL168300A IL 168300 A IL168300 A IL 168300A IL 168300 A IL168300 A IL 168300A IL 16830005 A IL16830005 A IL 16830005A IL 168300 A IL168300 A IL 168300A
- Authority
- IL
- Israel
- Prior art keywords
- catalase
- cells
- peroxisomes
- aging
- peroxisomal
- Prior art date
Links
- 102000016938 Catalase Human genes 0.000 title abstract 4
- 108010053835 Catalase Proteins 0.000 title abstract 4
- 101710195300 Peroxisomal catalase Proteins 0.000 title 1
- 210000002824 peroxisome Anatomy 0.000 abstract 4
- 230000032683 aging Effects 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 108010085186 Peroxisomal Targeting Signals Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000008676 import Effects 0.000 abstract 2
- 210000003463 organelle Anatomy 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 239000003642 reactive oxygen metabolite Substances 0.000 abstract 2
- 101000987688 Arabidopsis thaliana Peroxisome biogenesis protein 5 Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 101000913652 Mus musculus Fibronectin type III domain-containing protein 5 Proteins 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 230000008436 biogenesis Effects 0.000 abstract 1
- 230000004700 cellular uptake Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000005260 human cell Anatomy 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000009456 molecular mechanism Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42210002P | 2002-10-30 | 2002-10-30 | |
| PCT/US2003/034512 WO2004042011A2 (en) | 2002-10-30 | 2003-10-30 | Promotion of peroxisomal catalase function in cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL168300A true IL168300A (en) | 2010-11-30 |
Family
ID=32312481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL168300A IL168300A (en) | 2002-10-30 | 2005-05-01 | Modified catalase proteins useful for promotion of peroxisomal catalase function in cells |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US7601366B2 (enExample) |
| EP (1) | EP1578938B1 (enExample) |
| JP (2) | JP2006515168A (enExample) |
| AT (1) | ATE510009T1 (enExample) |
| AU (1) | AU2003287289B2 (enExample) |
| IL (1) | IL168300A (enExample) |
| NZ (1) | NZ540429A (enExample) |
| WO (1) | WO2004042011A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10142467A1 (de) * | 2001-08-31 | 2003-03-20 | Basf Ag | Neue Pyruvatdecarboxylase, ihre Herstellung und Verwendung |
| KR100472938B1 (ko) * | 2002-10-31 | 2005-03-11 | 학교법인 한림대학교 | 세포침투 효율을 향상시킨 수송도메인-목표단백질-수송도메인 융합단백질 및 그 용도 |
| JP2021520204A (ja) * | 2018-04-03 | 2021-08-19 | コーネル・ユニバーシティーＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ | 酸化ストレスに対する遺伝子療法 |
| WO2020160251A1 (en) * | 2019-01-30 | 2020-08-06 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating age-related diseases or conditions |
| CN116999550A (zh) * | 2022-04-28 | 2023-11-07 | 中山大学 | 过氧化物酶体增殖物激活受体激动剂在制备抗衰老药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5824469A (en) * | 1986-07-17 | 1998-10-20 | University Of Washington | Method for producing novel DNA sequences with biological activity |
| EP0635572A3 (en) * | 1993-06-25 | 1995-03-08 | Hoffmann La Roche | Biotin biosynthesis in Bacillus subtilis. |
| WO1998048004A1 (en) * | 1997-04-18 | 1998-10-29 | The Wistar Institute Of Anatomy And Biology | Method and compositions for stabilizing unstable gene transcripts |
| US20040058856A1 (en) * | 2000-07-26 | 2004-03-25 | Soo-Young Choi | Oligolysine transducing domain, oligolysine-cargo molecule complex and uses thereof |
-
2003
- 2003-10-30 EP EP03781522A patent/EP1578938B1/en not_active Expired - Lifetime
- 2003-10-30 AT AT03781522T patent/ATE510009T1/de not_active IP Right Cessation
- 2003-10-30 JP JP2004550263A patent/JP2006515168A/ja active Pending
- 2003-10-30 US US10/533,124 patent/US7601366B2/en not_active Expired - Fee Related
- 2003-10-30 WO PCT/US2003/034512 patent/WO2004042011A2/en not_active Ceased
- 2003-10-30 AU AU2003287289A patent/AU2003287289B2/en not_active Ceased
- 2003-10-30 NZ NZ540429A patent/NZ540429A/en not_active IP Right Cessation
-
2005
- 2005-05-01 IL IL168300A patent/IL168300A/en not_active IP Right Cessation
-
2009
- 2009-09-29 US US12/568,960 patent/US8663630B2/en not_active Expired - Fee Related
-
2010
- 2010-07-20 JP JP2010163435A patent/JP2010239971A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004042011A2 (en) | 2004-05-21 |
| AU2003287289B2 (en) | 2009-05-28 |
| US20060141598A1 (en) | 2006-06-29 |
| JP2010239971A (ja) | 2010-10-28 |
| EP1578938B1 (en) | 2011-05-18 |
| JP2006515168A (ja) | 2006-05-25 |
| EP1578938A2 (en) | 2005-09-28 |
| ATE510009T1 (de) | 2011-06-15 |
| US20100098679A1 (en) | 2010-04-22 |
| US8663630B2 (en) | 2014-03-04 |
| EP1578938A4 (en) | 2007-01-10 |
| WO2004042011A3 (en) | 2005-09-29 |
| US7601366B2 (en) | 2009-10-13 |
| AU2003287289A1 (en) | 2004-06-07 |
| NZ540429A (en) | 2009-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005021579A3 (en) | Epo mimetic peptides and fusion proteins | |
| WO2004043361A3 (en) | Compositions and methods for the treatment of natural killer cell related diseases | |
| ATE551048T1 (de) | Proteinhydrolysate enthaltende kosmetische zusammensetzungen | |
| ATE417595T1 (de) | Keratin-bindende polypeptide | |
| MX336118B (es) | Expresion hibrida y en tandem de proteinas de neisseria. | |
| WO2005021592A3 (en) | Enhancing the circulating half-life of interleukin-2 proteins | |
| WO2004024068A3 (en) | Novel composition and methods for the treatment of immune related diseases | |
| NZ576467A (en) | Smoothened polypeptides and methods of use | |
| EP2266599A3 (en) | Therapeutic composition with a botulinum neurotoxin | |
| WO2005023866A3 (en) | Peptides that inhibit complement activation | |
| WO2007064917A3 (en) | Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins | |
| WO2005023185A3 (en) | Pharmaceutical compositions and method of using levodopa and carbidopa | |
| MX2008004734A (es) | Composicion rica en leucina. | |
| EP0754229A1 (en) | Alfamin: a human serum albumin-like protein | |
| WO2007139997A3 (en) | Methods for site-specific pegylation | |
| WO2006057003A3 (en) | Induction of neurogenesis and stem cell therapy in combination with copolymer 1 | |
| WO2005074970A3 (en) | Neuroprotective dietary supplement | |
| WO2009064366A3 (en) | Methods and compositions for protein labeling using lipoic acid ligases | |
| WO2002034202A3 (en) | Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress | |
| WO2004039832A3 (en) | Leptin-related peptides | |
| IL168300A (en) | Modified catalase proteins useful for promotion of peroxisomal catalase function in cells | |
| AU2003235874A1 (en) | Skin collagen production promoter | |
| WO2004019965A3 (en) | Thymus-based tolerogenic approaches for type i diabetes. | |
| WO2008149668A1 (ja) | タンパク質含有組成物 | |
| WO2000070665A3 (en) | Long lasting anti-angiogenic peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |